

Xavier Leroy

Chief Technology Officer, Domain Therapeutics

Xavier Leroy, PhD, started his Biotech/Pharma career at Novartis, then Axovan, before spending more than thirteen years at Actelion Pharmaceuticals Ltd (Switzerland) in positions of increasing seniority.

As Associate Director, he developed multiple GPCR-targeting programs in the field of neuroscience, inflammation, Immuno-oncology. Several of his programs moved to Clinical trials.

Most recently he was Head of Drug Discovery at Belgium-based iTeos Therapeutics, overseeing the development of the company's immuno-oncology portfolio, as A2AR and TIGIT programs.

Xavier is a member of the management committee of European Cooperation in Science and Technology (COST) where he actively participates in the European Research Network on Signal Transduction.

At Domain Therapeutics, he leads the biology, pharmacology and immunology departments, and is expanding the company portfolio with the discovery and development of therapeutic monoclonal antibodies targeting GPCRs.

Accomplishments:

- Management Committee Member of European Cooperation in Science and Technology (COST) where he actively participates in the European Research Network on Signal Transduction.
- GPCR Specialist - 3 GPCRs deorphanization, Start-Ups Scientific Advisor